Overview

Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma

Status:
Completed
Trial end date:
2021-06-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability and overall response rate of carfilzomib in combination with dexamethasone for the treatment of multiple myeloma in China.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Collaborator:
Onyx Therapeutics, Inc.
Treatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate